Hanmi Pharmaceutical has launched a sweeping organizational overhaul to strengthen competitiveness in key businesses such as obesity and oncology. It is the first large-scale reorganization since the shift to a professional management system, aimed at accelerating the execution of its 2030 mid- to long-term growth strategy.
Hanmi Pharmaceutical said on the 8th that it reorganized its structure around four divisions: ▲ innovation growth ▲ sustainable growth ▲ future growth ▲ growth support. It is a measure to flesh out the "2030 mid- to long-term vision" that the Hanmi Group released last year.
At the time, the Hanmi Group presented obesity, anti-aging, digital healthcare, and Robotics as new growth pillars and said it would strengthen its new drug and bio businesses while pushing to expand new businesses.
The core of this reorganization is the creation of the "innovation growth division." To boost execution of its growth strategy centered on obesity treatments, the company placed the new product development center, marketing center, Pyeongtaek manufacturing center, pharmaceutical innovation center, and overseas sales team under one organization. The aim is to raise business synergy by linking everything from research and development (R&D) to production and sales.
The existing R&D center was reorganized into the "future growth division." Under it, the company established the obesity metabolism center, oncology center, and convergence center to strengthen early pipeline discovery and the independence of research and development.
The domestic sales organization was elevated to the "sustainable growth division." The move is intended to maintain competitiveness in the cardiovascular and urology markets while responding to expansion into new therapeutic areas. The company plans to enhance market responsiveness by raising the expertise of the sales organization.
The "growth support division" houses the Paltan manufacturing center and the business management center. The company also said it strengthened the independence of the clinical quality assurance (QA) and pharmacovigilance (PV) organizations to build an operating system that meets global standards.
Along with this, Hanmi Pharmaceutical will also run a "portfolio committee" that oversees clinical investment and development strategy. It plans to reorganize the clinical center under the committee to serve as a control tower that decides new projects and development priorities.
Chief Executive Hwang Sang-yeon recently held an internal town hall meeting to share the direction of the reorganization with employees. Hwang said, "We focused on reducing boundaries between departments and concentrating capabilities on business goals," and added, "Through a system in which each division is organically connected, we will pursue innovative new drug development and sustainable growth."